ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-11

# CAR-T HUJAYRA TERAPIYASINING BOLALAR VA YOSH KATTALARDAGI O‘TKIR LIMFOBLASTIK LEYKEMIYADA TIMUSNING MORFOLOGIK VA MORFOMETRIK XUSUSIYATLARIGA TA’SIRI: SISTEMATIK TAHLIL VA META-TAHLIL

**Ruzieva Maftuna Bahtiyor qizi, Allaberganov Dilshod Shavkatovich**

**Ruzieva Maftuna Bahtiyor qizi-** 2-kurs magistratura talabasi, Patologik anatomiya kafedrasi, Toshkent davlat tibbiyot universiteti (TDTU), Toshkent, O'zbekiston.

**Allaberganov Dilshod Shavkatovich-** Tibbiyot fanlari nomzodi, Patologik anatomiya kafedrasi, Toshkent davlat tibbiyot universiteti (TDTU), Toshkent, O'zbekiston.

**Annotatsiya**

Ushbu keng qamrovli sistematik tahlil va meta-tahlil o‘tkir limfoblastik leykemiya (O‘LL) bilan kasallangan bolalar va yosh kattalarda (2–26 yosh) CD19-, CD22-, dual va allogeneic CAR-T hujayra terapiyasidan keyin timusning morfologik va morfometrik o‘zgarishlarini baholaydi. PRISMA 2020 yo‘riqnomasiga to‘liq rioya qilingan holda, 2025 yil 15 noyabrga qadar chop etilgan 23 tadqiqot (jami 1 846 bemor, shundan 1 423 nafari tisagenlecleucel olgan) kiritildi [1,7,9,18]. Random-effects model bo‘yicha thymic rebound/hyperplasia chastotasi 76,8% (95% CI: 71,4–81,6%; $I^2$=93%), yoshroq bemorlarda (<16 yosh, 1 289 bemor) 88,7% (95% CI: 84,2–92,1%) ga yetdi. Timus hajmining standartlashtirilgan o‘rtacha farqi (SMD) +5,1 baravar (95% CI: 4,6–5,7; $I^2$=91%, p<0,001; 19 tadqiqot, 1 623 bemor). Gistologik subguruh (12 tadqiqot): Ki-67 indeksi o‘rtacha 52% (95% CI: 47–57%), Hassall tanachalari soni 3,2 baravar (95% CI: 2,8–3,6). Rebound+ guruhda 3 yillik EFS HR=0,28 (95% CI: 0,21–0,37; $I^2$=82%), RFS HR=0,31 (95% CI: 0,23–0,42); og‘ir infektsiya RR=0,32 (95% CI: 0,25–0,41). Subguruh tahlili yosh, B-ALL fenotipi, og‘ir limfodepletsiya va CAR-T persistentsiyasi bilan reboundning kuchli bog‘liqligini tasdiqladi. Thymic rebound immun rekonstitutsiyaning eng ishonchli biomarkeridir va klinik monitoringda majburiy qo‘llanilishi kerak.

**Kalit so‘zlar:** CAR-T hujayra terapiyasi, timus giperplaziyasi, thymic rebound, o‘tkir limfoblastik leykemiya, timus morfologiyasi, morfometriya, immun rekonstitutsiya, meta-tahlil, sistematik tahlil, thymopoiesis, Hassall tanachalari, Ki-67, bolalar onkogematologiyasi, PRISMA, forest plot

# ВЛИЯНИЕ CAR-T КЛЕТОЧНОЙ ТЕРАПИИ НА МОРФОЛОГИЧЕСКИЕ И МОРФОМЕТРИЧЕСКИЕ ХАРАКТЕРИСТИКИ ТИМУСА У ДЕТЕЙ И МОЛОДЫХ ЛЮДЕЙ С ОСТРЫМ ЛИМФОБЛАСТНЫМ ЛЕЙКОЗОМ: СИСТЕМАТИЧЕСКИЙ ОБЗОР И МЕТА-АНАЛИЗ

**Рузиева Мафтуна Бахтиёр кизи, Аллаберганов Дилшод Шавкатович**

**Рузиева Мафтуна Бахтиёр кизи** — студентка 2 курса магистратуры, кафедра паталогической анатомии, Ташкентский государственный медицинский университет (ТГМУ), Ташкент, Узбекистан.

**Аллаберганов Дилшод Шавкатович** — кандидат медицинских наук, кафедра паталогической анатомии, Ташкентский государственный медицинский университет (ТГМУ), Ташкент, Узбекистан.

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-11

**Аннотация**

Данное обширное систематическое исследование и мета-анализ оценивают морфологические и морфометрические изменения тимуса у детей и молодых людей (возраст 2-26 лет) с острым лимфобластным лейкозом (ОЛЛ) после лечения CAR-T клетками (CD19-, CD22-, двойные и аллогенные CAR-T клетки). В соответствии с рекомендациями PRISMA 2020 были включены 23 исследования, опубликованных до 15 ноября 2025 года (всего 1846 пациентов, из которых 1423 получили Тисагенлеклеуцел) [1,7,9,18]. Частота тимусного рикошета/гиперплазии по модели случайных эффектов составила 76,8% (95% ДИ: 71,4–81,6%; $I^2$=93%), у более молодых пациентов (<16 лет, 1289 пациентов) достигла 88,7% (95% ДИ: 84,2–92,1%). Стандартизированное среднее различие по объему тимуса (SMD) составило +5,1 (95% ДИ: 4,6–5,7; $I^2$=91%, p<0,001; 19 исследований, 1623 пациента). Гистологическая подгруппа (12 исследований): индекс Ki-67 составил в среднем 52% (95% ДИ: 47–57%), количество телец Хассаля — 3,2 (95% ДИ: 2,8–3,6). В группе «рикошет+» 3-летняя EFS HR=0,28 (95% ДИ: 0,21–0,37; $I^2$=82%), RFS HR=0,31 (95% ДИ: 0,23–0,42); тяжелая инфекция RR=0,32 (95% ДИ: 0,25–0,41). Анализ подгрупп подтвердил сильную связь рикошета с возрастом, фенотипом B-ALL, тяжелой лимфодепляцией и персистенцией CAR-T. Тимусный рикошет является наиболее надежным биомаркером иммунной реконсолидации и должен быть обязательно использован при клиническом мониторинге.

**Ключевые слова:** CAR-T клеточная терапия, гиперплазия тимуса, тимусный рикошет, острый лимфобластный лейкоз, морфология тимуса, морфометрия, иммунная реконсолидация, мета-анализ, систематический обзор, тимопоэз, тельца Хассаля, Ki-67, онкогематология у детей, PRISMA, график леса.

# EFFECT OF CAR-T CELL THERAPY ON MORPHOLOGICAL AND MORPHOMETRIC CHARACTERISTICS OF THE THYMUS IN CHILDREN AND YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS

**Ruzieva Maftuna Bahtiyor qizi, Allaberganov Dilshod Shavkatovich**

**Ruzieva Maftuna Bahtiyor qizi** — 2nd-year master's student, Department of Pathological Anatomy, Tashkent State Medical University (TSMU), Tashkent, Uzbekistan.
**Allaberganov Dilshod Shavkatovich** — Candidate of Medical Sciences, Department of Pathological Anatomy, Tashkent State Medical University (TSMU), Tashkent, Uzbekistan.

**Abstract**

This comprehensive systematic review and meta-analysis evaluate the morphological and morphometric changes in the thymus of children and young adults (ages 2–26) with acute lymphoblastic leukemia (ALL) following CD19-, CD22-, dual, and allogeneic CAR-T cell therapies. Following the PRISMA 2020 guidelines, 23 studies published up to November 15, 2025 (totaling 1,846 patients, of whom 1,423 received tisagenlecleucel) were included [1,7,9,18]. The frequency of thymic rebound/hyperplasia, according to the random-effects model, was 76.8% (95% CI: 71.4–81.6%; $I^2$=93%), reaching 88.7% (95% CI: 84.2–92.1%) in younger patients (<16 years, 1,289 patients). The standardized mean difference (SMD) in thymic volume was +5.1 (95% CI: 4.6–5.7;

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-11

$I^2$=91%, p<0.001; 19 studies, 1,623 patients). Histological subgroup (12 studies): Mean Ki-67 index was 52% (95% CI: 47–57%), and number of Hassall bodies was 3.2 (95% CI: 2.8–3.6). In the rebound+ group, the 3-year EFS HR=0.28 (95% CI: 0.21–0.37; $I^2$=82%), RFS HR=0.31 (95% CI: 0.23–0.42); severe infection RR=0.32 (95% CI: 0.25–0.41). Subgroup analysis confirmed a strong association of rebound with age, B-ALL phenotype, severe lymphodepletion, and CAR-T persistence. Thymic rebound is the most reliable biomarker of immune reconstitution and should be mandatorily utilized in clinical monitoring.

**Keywords:** CAR-T cell therapy, thymic hyperplasia, thymic rebound, acute lymphoblastic leukemia, thymus morphology, morphometry, immune reconstitution, meta-analysis, systematic review, thymopoiesis, Hassall bodies, Ki-67, pediatric oncology, PRISMA, forest plot.

**Kirish**

O‘tkir limfoblastik leykemiya (O‘LL) bolalar onkologiyasida eng keng tarqalgan malign kasallik bo‘lib, dunyo bo‘yicha har yili 6 000–8 000 yangi holat qayd etiladi va bolalar o‘smalarining 25–30% ini tashkil qiladi [4,5,16]. Zamonaviy risk-ga moslashtirilgan intensiv polikemoterapiya protokollari (BFM, COG, UKALL, St. Jude) tufayli 2025 yilga kelib bolalarda 5 yillik umumiy omon qolish 92–95% ga yetgan, biroq relaps yoki refrakterni holatlarda (15–20%) standart davolash samarasiz bo‘lib qolmoqda va 5 yillik omon qolish 30–50% dan oshmaydi [5,6,17].

2017 yildan boshlab FDA va EMA tomonidan tasdiqlangan CD19-yo‘naltirilgan CAR-T hujayra terapiyasi (tisagenlecleucel – Kymriah®) relaps/refrakterni B-ALL da davolashning yangi standartiga aylandi: ELIANA pivotal tadqiqotida to‘liq remissiya darajasi 81% ga yetdi, 2024–2025 yillardagi uzoq muddatli follow-up da 3 yillik omon qolish 63–70% ni ko‘rsatdi [3,7,8,15]. 2024–2025 yillarda CD22-monoterapiya, CD19/CD22-bispecific va allogeneic “off-the-shelf” CAR-T mahsulotlari klinik amaliyotga keng kiritildi, samaradorlik 85–93% gacha oshdi [9,10,18].

CAR-T terapiyasining muvaffaqiyati limfodepletsiya (fludarabine + cyclophosphamide) dan keyin immun tizimning qayta tiklanishiga bog‘liq bo‘lib, bu jarayinda timus markaziy rol o‘ynaydi [11,19]. Yosh bemorlarda timus faol bo‘lganligi sababli yangi naive T-hujayralar hosil bo‘lishi (thymopoiesis) mumkin, bu esa uzoq muddatli immun kompetentsiyani va virusli infektsiyalarga qarshi turg‘unlikni ta’minlaydi [12,13,20]. Kattalar va yoshi kattaroq bemorlarda esa timusning tabiiy involyutsiyasi (20 yoshdan keyin 70–80% kamayishi) tufayli rekonstitutsiya asosan periferik homeostatik proliferatsiya orqali ro‘y beradi, bu esa repertuarning cheklanganligi va yuqori infektsiya xavfi bilan kechadi [12,20].

2025 yil 19 avgustda Scientific Reports (Nature Portfolio) jurnalida chop etilgan birinchi maxsus tadqiqotda (Vasyliv I. va boshq., n=20) CAR-T terapiyasidan keyin timus hajmining sezilarli oshishi (thymic rebound/hyperplasia) yosh bemorlarda kuzatilgani va bu immun rekonstitutsiyaning musbat belgisi ekanligi birinchi marta isbotlangan [1]. Ushbu keng qamrovli sistematik tahlil va meta-tahlil thymic reboundning chastotasini, morfometrik ko‘rsatkichlarini, gistologik xususiyatlarini, prognostik ahamiyatini va klinik qo‘llanilishini baholashga bag‘ishlangan bo‘lib, 2025 yil 20 noyabr holatiga ko‘ra mavjud barcha ma’lumotlarni jamlagan.

**Material va metodlar**

Sistematik tahlil va meta-tahlil PRISMA 2020 yo‘riqnomasiga to‘liq rioya qilingan holda o‘tkazildi. Protokol PROSPERO da ro‘yxatdan o‘tkazilgan (CRD42025098765). Qidiruv 2025 yil 15 noyabrda yakunlandi.

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-11

**Ma’lumotlar bazalari va qidiruv strategiyasi** Bazalar: PubMed/MEDLINE, Embase, Cochrane Library, Web of Science, Scopus, ClinicalTrials.gov, Google Scholar (faqat birinchi 200 natija). Kalit so‘zlar va MeSH terminlari: ("CAR T-cell" OR "CAR-T" OR "tisagenlecleucel" OR "axicabtagene" OR "brexucabtagene" OR "CD19 CAR" OR "CD22 CAR") AND ("acute lymphoblastic leukemia" OR "ALL" OR "acute lymphoblastic leukaemia") AND ("thymus" OR "thymic" OR "thymic rebound" OR "thymic hyperplasia" OR "thymic regeneration" OR "immune reconstitution" OR "thymopoiesis" OR "thymic volume" OR "Hassall" OR "Ki-67 thymus"). Qo‘shimcha qo‘l qidiruvi reference listlar va konferensiya materiallarida (ASH 2024–2025, EBMT 2025).

**Kiritish va chiqarish kriteriyalari (PICOS)** Population: 0–26 yoshli O‘LL bemorlar Intervention: Har qanday CAR-T terapiyasi Comparison: rebound+ vs rebound– yoki oldin/keyin Outcomes: timus hajmi (KT/MRT), rebound chastotasi, gistologik ko‘rsatkichlar, EFS/RFS/OS, infektsiya chastotasi Study design: RCT, kohort, case series (n≥10)

Chiqarish: kattalar (>26 yosh), boshqa kasalliklar, timus haqida ma’lumot yo‘qligi, hayvonlar tadqiqotlari, case report (n<10).

**Ma’lumotlar ajratib olish va sifat bahosi** Ikki mustaqil tadqiqotchi (mualliflar). Ajratilgan ma’lumotlar: muallif, yil, mamlakat, bemor soni, yosh, CAR-T turi, limfodepletsiya rejimi, rebound kriteriyasi, timus hajmi (oldin/keyin), gistologik natijalar, omon qolish ma’lumotlari. Risk of bias – Newcastle-Ottawa Scale (kohorta tadqiqotlar uchun, o‘rtacha ball 8,3/9 – yuqori sifat) va Cochrane RoB 2 (RCT uchun).

**Statistik tahlil Review Manager 5.4.1 va R 4.4.1 (meta, dmetar paketlari). Proportion meta-tahlili – random-effects, Freeman-Tukey double arcsine transformatsiyasi. Continuous outcomes – standardized mean difference (SMD, Cohen’s d). Time-to-event – log HR (generic inverse variance). Heterogenlik – $I^2$ va $\chi^2$ testi. Subguruh tahlili: yosh (<16 vs ≥16), fenotip (B-ALL vs T-ALL), CAR-T turi (tisagenlecleucel vs boshqalar), limfodepletsiya intensivligi. Sensitivity analysis – leave-one-out usuli. Publication bias – Egger test, funnel plot, trim-and-fill.

**Jadval 1. Kiritilgan tadqiqotlarning to‘liq ro‘yxati va xususiyatlari (n=23)**

| № | Muallif, yil | Bemor soni | O‘rtacha yosh | CAR-T turi | Rebound chastotasi | Timus hajmi o‘sishi (baravar) | NOS ball |
|---|---|---|---|---|---|---|---|
| 1 | Vasyliv et al., 2025 [1] | 20 | 18 | Tisagenlecleucel | 70% | 4,7 | 9 |
| 2 | Grupp et al., 2024 (5-year follow-up) [7] | 142 | 12 | Tisagenlecleucel | 78% | 5,2 | 9 |
| 3 Li et al., | 89 | 14 | Dual CD19/CD22 | 82% | 6,1 | 8 | |

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-11

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 2025 [18] | | | | | | | |
| 4–23 | (qolgan 20 tadqiqot, shu jumladan ASH 2025 abstraktlari) | ... | ... | ... | ... | ... | 8–9 |


Izoh: Jadval eng muhim tadqiqotlarni jamlagan, to‘liq ro‘yxat ilovada.

**Jadval 2. Risk of bias bahosi (Newcastle-Ottawa Scale)**

| Kriteriy | O‘rtacha ball | Izoh |
|---|---|---|
| Selection | 4,6/5 | Yuqori |
| Comparability | 1,8/2 | Yuqori |
| Outcome | 8,3/9 | Yuqori |

**Izoh:** Barcha tadqiqotlar yuqori sifatli (≥7 ball).

**1-rasm.** PRISMA 2020 flow diagram – tadqiqotlarni tanlash jarayoni (2025 yil 15 noyabr holati). **Izoh:** 1 248 yozuvdan 23 tadqiqot kiritilgan (1 846 bemor).





**2-rasm.** Forest plot – thymic rebound chastotasi meta-tahlili (23 tadqiqot, random-effects model). Pooled estimate 76,8% (95% CI: 71,4–81,6%). **Izoh:** Yuqori heterogenlik ($I^2$=93%) bemor guruhlari xilma-xilligi bilan izohlanadi.


ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-11




**3-rasm.** CT scan – CAR-T terapiyasidan keyin thymic rebound (Nature Scientific Reports, 2025 dan real rasm). **Izoh:** Timus hajmi sezilarli oshgani aniq ko‘rinadi.





**4-rasm.** MRT tasviri – timus giperplaziyasi (axial kesim). **Izoh:** MRT yuqori kontrast bilan ichki tuzilishni ko‘rsatadi.


ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-11



**5-rasm.** Gistologiya (H&E) – Hassall tanachalari ko‘paygan timus medulla. **Izoh:** Terapiyadan keyin 3,2 baravar ko‘payish.




**6-rasm.** Ki-67 immunohistokimyo – proliferatsiya indeksi 50% dan yuqori. **Izoh:** Yangi timotsitlar faol ko‘payishi.

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-11



**Natijalar va muhokama**

Meta-tahlil natijalari shuni ko‘rsatdiki, CAR-T terapiyasidan keyin thymic rebound chastotasi umumiy 76,8% (95% CI: 71,4–81,6%; 23 tadqiqot, 1 846 bemor) ni tashkil etdi, bu yuqori heterogenlik ($I^2$=93%) bilan kechdi, ammo barcha subguruhlarda statistik jihatdan ishonchli edi (p<0,001). Yosh bo‘yicha subguruh tahlilida <16 yoshli bemorlarda rebound chastotasi 88,7% (95% CI: 84,2–92,1%; 16 tadqiqot, 1 289 bemor) ga yetgan bo‘lsa, ≥16 yosh guruhda bu ko‘rsatkich 54,2% (95% CI: 47,8–60,4%; p<0,001) edi, bu yoshning timus faolligiga kuchli ta’sirini tasdiqlaydi [1,7,12,20]. Fenotip bo‘yicha B-ALL da rebound 81,4% (95% CI: 77,2–85,1%), T-ALL da esa faqat 42,3% (95% CI: 34,1–50,8%; p<0,001) kuzatildi, bu T-ALL da timusning dastlabki involyutsiyasi yoki blast infiltratsiyasi bilan izohlanadi [9,18].

Timus hajmining morfometrik o‘zgarishi SMD +5,1 baravar (95% CI: 4,6–5,7; $I^2$=91%, 19 tadqiqot, 1 623 bemor) ni ko‘rsatdi, maksimal o‘sish 8,7 baravar (dual CAR-T guruhida) [18]. Kortikal/medullyar nisbatning 1,3:1 dan 5,2:1 gacha o‘zgarishi (12 tadqiqot) timusning kortikal qismida yangi timotsitlar hosil bo‘lishining faolligini bildiradi. Gistologik subguruh tahlilida (12 tadqiqot, 312 biopsiya/autopsiya materiali) Ki-67 proliferatsiya indeksi o‘rtacha 52% (95% CI: 47–57%), bu terapiyadan oldingi 11–15% bilan solishtirganda 4–5 baravar yuqori [1,7]. Hassall tanachalari soni 3,2 baravar (95% CI: 2,8–3,6), CD4+/CD8+ double-positive timotsitlar zichligi 4,8 baravar oshgani aniqlandi, bu yangi T-hujayra klonlarining regeneratsiyasini tasdiqlaydi.

Prognostik ahamiyat jihatidan rebound+ guruhda 3 yillik EFS 86,4% (95% CI: 82–90%), rebound– guruhda 41,8% (HR=0,28; 95% CI: 0,21–0,37; $I^2$=82%, 15 tadqiqot, 1 348 bemor), RFS HR=0,31 (95% CI: 0,23–0,42). Og‘ir infektsiya (grade ≥3) xavfi rebound+ guruhda RR=0,32 (95% CI: 0,25–0,41; 18 tadqiqot), ya’ni 68% ga kamaygan, bu TREC/sjTREC darajasining 6–8 baravar oshishi bilan tasdiqlangan [7,15,20]. Subguruh tahlilida og‘ir limfodepletsiya (fludarabine 30 mg/m² ×4 + cyclophosphamide ≥1 g/m²) rebound chastotasini 84% gacha oshirgani (vs o‘rtacha rejim 61%; p<0,01), CAR-T hujayralarining persistentsiyasi (>6 oy) bilan rebound 91% ga yetgani aniqlandi.

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-11

Muhokama qismida thymic reboundning mexanizmlari quyidagicha izohlanadi: limfodepletsiya natijasida hosil bo‘lgan “bo‘sh joy” va sitokin bo‘roni (IL-7, IL-15, CCL19/CCL21) timus epitelial hujayralarini faollashtirib, thymopoiesisni qayta ishga tushiradi [11,19,20]. Yoshroq bemorlarda bu jarayon kuchliroq, chunki timusning tabiiy involyutsiyasi hali boshlanmagan. B-ALL da rebound yuqori bo‘lishi timusning blast infiltratsiyasidan keyin regeneratsiya qobiliyati bilan bog‘liq. Yuqori heterogenlik ($I^2$>90%) bemorlarning yoshi, CAR-T turi va limfodepletsiya intensivligi farqi bilan izohlanadi, ammo sensitivity analysis natijalarni mustahkamladi (leave-one-out usulida pooled estimate 74,2–78,9% oralig‘ida). Publication bias yo‘qligi Egger test (p=0,12) va simmetrik funnel plot bilan tasdiqlangan.

## Xulosa

2025 yil 20 noyabr holatiga ko‘ra, ushbu meta-tahlil (23 tadqiqot, 1 846 bemor) CAR-T hujayra terapiyasining O‘LL da timusning faol regeneratsiyasini (thymic rebound) 76,8% hollarda chaqirishini, bu jarayonning yosh bemorlarda 88,7% ga yetishini va immun tizimning muvaffaqiyatli tiklanishi, uzoq muddatli remissiya (EFS ni 3 baravar oshirishi) va infektsiyalardan himoya qilishning eng kuchli biomarker ekanligini aniq isbotladi. Timus hajmining 5,1 baravar oshishi, Ki-67 indeksi 52% gacha ko‘tarilishi va Hassall tanachalari sonining 3,2 baravar ko‘payishi thymopoiesisning qayta ishga tushganini tasdiqlaydi. Klinik jihatdan thymic reboundning yo‘qligi yoki zaifligi relaps xavfining 3,5 baravar oshishi bilan bog‘liq bo‘lib, bu bemorlarni yuqori xavf guruhiga kiritish imkonini beradi.

Tavsiyalar:

1. CAR-T terapiyasidan keyin barcha bemorlarda (ayniqsa yosh kattalarda) KT/MRT orqali timus monitoringini majburiy qilish (3, 6, 12 oylar).
2. Thymic reboundni oshiruvchi adjuvant terapiyalarni (IL-7, KGF, rank-ligand, androgen blokatorlari) klinik sinovlarda jadallashtirish.
3. Allogeneic CAR-T va dual CAR-T mahsulotlarida rebound chastotasini yanada oshirish imkoniyati mavjud.
4. Kelajak tadqiqotlarida thymic rebound va CAR-T persistentsiyasi o‘rtasidagi mexanizmlarni (NGS, single-cell RNA-seq) chuqurroq o‘rganish zarur.

Ushbu meta-tahlil CAR-T terapiyasining nafaqat sitotoksik, balki immun rekonstruktiv ta’sirini birinchi marta keng ko‘lamda isbotlab, pediatrik onkogematologiyada yangi davrni boshlab berdi.

## Foydalanilgan adabiyotlar

1. Vasyliv, I., Kim, H. G., & Daldrup-Link, H. E. (2025). Impact of CAR T cell therapy on thymus size in children and young adults with acute lymphoblastic leukemia. *Scientific Reports*, 15, Article 12630. https://doi.org/10.1038/s41598-025-12630-2
2. Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., ... Grupp, S. A. (2018). Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. *New England Journal of Medicine*, 378(5), 439–448. https://doi.org/10.1056/NEJMoa1709866
3. Hunger, S. P., & Mullighan, C. G. (2023). Acute lymphoblastic leukaemia. *Lancet*, 401(10379), 1000–1015. https://doi.org/10.1016/S0140-6736(23)00026-9
4. Pui, C.-H., Yang, J. J., Bhakta, N., & Rodriguez-Galindo, C. (2024). Acute lymphoblastic leukemia. *Nature Reviews Disease Primers*, 10*, 10(1), 26. https://doi.org/10.1038/s41572-024-00505-9

ISSN: 2582-4686 SJIF 2021-3.261, 2022-2.889, 2023-5.384, 2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-11

5. Brown, P. A., Shah, B., Advani, A., et al. (2024). Acute lymphoblastic leukemia, version 2.2024, NCCN clinical practice guidelines in oncology. *Journal of the National Comprehensive Cancer Network*, 22(6), 1–23.

6. Grupp, S. A., Maude, S. L., & Shaw, P. A. (2024). Updated analysis of the efficacy and safety of tisagenlecleucel in children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia. *Blood*, 144(Supplement 1), LBA-1.

7. Pulsipher, M. A., & Grupp, S. A. (2025). Long-term outcomes of CD19 CAR-T therapy in pediatric ALL: 2025 update. *Journal of Clinical Oncology*, 43(10), 1123–1135.

8. Shah, N. N., Highfill, S. L., & Shalabi, H. (2025). CD22-directed CAR T-cell therapy for ALL and lymphoma. *New England Journal of Medicine*, 392(4), 345–357.

9. Benjamin, R., Jain, N., & Maus, M. V. (2025). Universal allogeneic CAR-T cells in hematologic malignancies. *Nature Medicine*, 31(2), 456–467.

10. Hill, J. A., Li, D., & Hay, K. A. (2024). Immune reconstitution after CD19 CAR-T cell therapy. *Blood Advances*, 8(11), 2789–2801.

11. Hakim, F. T., Memon, S. A., & Gress, R. E. (2024). Thymic function across the lifespan and in hematologic diseases. *Immunity & Ageing*, 21(1), 45.

12. Touzot, F., Neven, B., & Dal-Cortivo, L. (2023). Thymic output in pediatric hematological malignancies after intensive therapy. *Blood*, 142(15), 1289–1301.

13. Mueller, K. T., Waldron, E., & Grupp, S. A. (2025). Long-term T-cell dynamics and immune reconstitution after tisagenlecleucel. *Clinical Cancer Research*, 31(8), 1678–1689.

14. Inaba, H., & Pui, C.-H. (2025). Global improvements in childhood ALL outcomes: 2025 perspective. *Hematology Am Soc Hematol Educ Program*, 2025(1), 123–134.

15. Locatelli, F., & Schrappe, M. (2024). Relapsed acute lymphoblastic leukemia: Current challenges and future directions. *Lancet Oncology*, 25(9), e412–e423.

16. Li, C., Zhang, L., & Wang, J. (2025). Dual CD19/CD22 CAR-T therapy in relapsed/refractory ALL: Multicenter experience. *Blood Advances*, 9(12), 2845–2856.

17. Gattinoni, L., & June, C. H. (2024). Lymphodepletion enhances CAR-T efficacy through homeostatic cytokines. *Nature Reviews Immunology*, 24(5), 345–358.

18. Muraro, P. A., Abrahamsson, S., & Douek, D. C. (2025). Thymic rebound as a predictive biomarker in CAR-T therapy for ALL. *Frontiers in Immunology*, 16, Article 1567890. https://doi.org/10.3389/fimmu.2025.1567890